Does Rallies show 13F holders for REGN?

Yes. Rallies tracks hedge fund and 13F ownership data for REGN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is REGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for REGN. It does not provide personalized investment advice.

REGN (Regeneron) Stock Analysis - Hedge Fund Holdings

Regeneron (REGN) is a publicly traded Healthcare sector company. As of May 20, 2026, REGN trades at $643.47 with a market cap of $66.02B and a P/E ratio of 15.17. REGN moved +2.94% today. Year to date, REGN is -18.81%; over the trailing twelve months it is +5.66%. Its 52-week range spans $476.49 to $1,070.00. Analyst consensus is strong buy with an average price target of $884.89. Rallies surfaces REGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns REGN stock?

Hedge funds tracked by Rallies that own REGN include Panagora Asset, Viking Global, Bridgewater Associates, Soros Fund, and Scion Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Regeneron.

REGN Key Metrics

Key financial metrics for REGN
Metric	Value
Price	$643.47
Market Cap	$66.02B
P/E Ratio	15.17
EPS	$42.56
Dividend Yield	0.94%
52-Week High	$1,070.00
52-Week Low	$476.49
Volume	866.13K
Avg Volume	0
Revenue (TTM)	$14.92B
Net Income	$4.42B
Gross Margin	0.00%

Top Hedge Funds Holding REGN

Panagora Asset holds 105.22K shares of REGN, changed +120.67% as of Mar 31, 2026.
Viking Global holds 97.74K shares of REGN, changed +95.99% as of Mar 31, 2025.
Bridgewater Associates holds 22.72K shares of REGN, changed -68.76% as of Mar 31, 2026.
Soros Fund holds 15.00K shares of REGN, changed -14.29% as of Mar 31, 2024.
Scion Asset holds 15.00K shares of REGN, changed +0.00% as of Jun 30, 2025.

Latest REGN News

Itepekimab Cuts Exacerbations 27.1% in AERIFY-1 but Misses in AERIFY-2 — May 20, 2026
Regeneron Shares Plunge 12% After Melanoma Drug Combo Misses Trial, Losing $9 Billion — May 18, 2026
Regeneron Downgraded After Fianlimab Trial Misses PFS Threshold (p=0.0627) — May 18, 2026
Regeneron Shares Plunge 10% After Melanoma Trial Misses PFS Endpoint — May 18, 2026
Nasdaq’s Top Decile Stocks Post 164% Rally, Regeneron Gains 48% — May 9, 2026

Recent REGN Insider Trades

RYAN ARTHUR F sold 1 (~$771.32) on Apr 1, 2026.
RYAN ARTHUR F sold 3 (~$2.32K) on Apr 1, 2026.
RYAN ARTHUR F sold 8 (~$6.19K) on Apr 1, 2026.

REGN Analyst Consensus

19 analysts cover REGN: 0 strong buy, 15 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $884.89.

Common questions about REGN

Who owns REGN stock?: Hedge funds tracked by Rallies that own REGN include Panagora Asset, Viking Global, Bridgewater Associates, Soros Fund, and Scion Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Regeneron.
Does Rallies show 13F holders for REGN?: Yes. Rallies tracks hedge fund and 13F ownership data for REGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is REGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for REGN. It does not provide personalized investment advice.